Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Post by newdaydawningon Aug 20, 2019 6:06pm

198 Views

Post# 30048344

The 80% figure isn't cast in stone

We can't forget that the trial could be halted early if we replicate Ph1b outcomes, post treatment optimization. I could be wrong about this, but if we repeat the results with as few as 40 patients, the trial might end early, presumably with a nod from the FDA.

Bullboard Posts

A Look into the Future of Chronic Pain Management